文献速递肿瘤 PET/CT神经核医学

18F-DOPA PET/CT 在儿童神经母细胞瘤诊断、疗效评估与预后中的作用:首项前瞻性研究

Diagnosis, Treatment Response, and Prognosis: The Role of 18F-DOPA PET/CT in Children Affected by Neuroblastoma in Comparison with 123I-mIBG Scan: The First Prospective Study.
PubMed 文献 · J Nucl Med · 2019-09-20

该前瞻性研究纳入 18 例儿童神经母细胞瘤患者,在诱导化疗前后分别行 18F-DOPA PET/CT 与 123I-mIBG 扫描加 SPECT/CT,比较两者的诊断灵敏度并评估预后价值。结果显示 18F-DOPA PET/CT 在分期和化疗后评估残留病灶方面灵敏度高于 123I-mIBG WBS,且治疗后 18F-DOPA 全身代谢负荷(WBMB>7.5)是唯一与无进展生存相关的因素。

要点

  • 18F-DOPA PET/CT 检测软组织及骨/骨髓转移的灵敏度显著高于 123I-mIBG WBS。
  • 化疗后 18F-DOPA PET/CT 评估残留病灶的灵敏度仍高于 123I-mIBG WBS。
  • 治疗后 18F-DOPA WBMB>7.5 是唯一与无进展生存相关的因素。

核心结论

  • 18F-DOPA PET/CT 在神经母细胞瘤分期及化疗后评估疾病残留方面比 123I-mIBG WBS 更灵敏。
  • 在时间-事件分析中,治疗后 18F-DOPA WBMB 是唯一与疾病进展相关的危险因素。

研究设计与样本

  • 前瞻性研究纳入 16 例高危和 2 例中危神经母细胞瘤患儿。
  • 所有患者在诱导化疗前后均行 18F-DOPA PET/CT 与 123I-mIBG 扫描加 SPECT/CT。
  • 分别进行基于患者和基于病灶的分析并计算灵敏度,比较两种模态。
  • 对 123I-mIBG 扫描和 18F-DOPA PET/CT 分别应用评分系统(123I-mIBG WBS 评分和全身代谢负荷 WBMB),评估其与主要危险因素及结局的关联。

主要发现

  • 基于患者分析,分期时 123I-mIBG WBS 检测原发肿瘤、软组织转移、骨或骨髓转移的灵敏度分别为 83%、50%、92%,18F-DOPA PET/CT 分别为 94%、92%、100%。
  • 基于病灶分析,分期时 18F-DOPA PET/CT 检测软组织转移和骨或骨髓转移的灵敏度分别为 86% 和 99%,显著高于 123I-mIBG WBS 的 41% 和 93%。
  • 治疗后基于患者分析,123I-mIBG WBS 检测原发肿瘤、软组织转移、骨或骨髓转移的灵敏度分别为 72%、33%、38%,18F-DOPA PET/CT 分别为 83%、75%、54%。
  • 治疗后基于病灶分析,18F-DOPA PET/CT 检测软组织转移和骨或骨髓转移的灵敏度分别为 77% 和 86%,显著高于 123I-mIBG WBS 的 28% 和 69%。
  • 随访期间发生 8 例疾病进展和 5 例死亡;多因素分析中仅治疗后 18F-DOPA WBMB(>7.5)与无进展生存相关。

关键数值与推荐

  • 123I-mIBG WBS 评分和 18F-DOPA 全身代谢负荷(WBMB)被用作评分系统。
  • 治疗后 18F-DOPA WBMB>7.5 与无进展生存相关。

临床怎么用

  • 在儿童神经母细胞瘤分期和化疗后评估中,可优先考虑 18F-DOPA PET/CT 以提高病灶检出灵敏度。
  • 治疗后 18F-DOPA WBMB>7.5 可提示疾病进展风险,辅助预后分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to evaluate the diagnostic role of 18F-3,4-dihydroxyphenylalanine (DOPA) PET/CT at the time of staging in children with neuroblastoma and to investigate its ability to assess treatment response. We also investigated the prognostic value of 18F-DOPA PET/CT at the same time points. Methods: We enrolled children with neuroblastoma at onset. Before and after induction chemotherapy, all patients underwent 18F-DOPA PET/CT and 123I-metaiodobenzylguanidine (MIBG) scanning plus SPECT/CT. 18F-DOPA PET/CT results were compared with those of 123I-MIBG whole-body scanning (WBS). For each modality, patient-based analysis and lesion-based analysis were performed and sensitivity was calculated. We applied scoring systems to 123I-MIBG scanning and 18F-DOPA PET/CT (i.e.,123I-MIBG WBS score and whole-body metabolic burden [WBMB], respectively) and evaluated the association between these parameters, the principal neuroblastoma risk factors, and outcome. Results: We enrolled 16 high-risk and 2 intermediate-risk neuroblastoma patients. On patient-based analysis, sensitivity in detecting primary tumors, soft-tissue metastases, and bone or bone-marrow metastases was 83%, 50%, and 92%, respectively, for 123I-MIBG WBS versus 94%, 92%, and 100%, respectively, for 18F-DOPA PET/CT. On lesion-based analysis, the sensitivity of 18F-DOPA PET/CT in detecting soft-tissue and bone or bone-marrow metastases was 86% and 99%, respectively-significantly higher than that of 123I-MIBG WBS, at 41% and 93%, respectively. After therapy, on patient-based analysis, the sensitivity in detecting primary tumors, soft-tissue metastases, and bone or bone-marrow metastases was 72%, 33%, and 38%, respectively, for 123I-MIBG WBS versus 83%, 75% and 54%, respectively, for 18F-DOPA PET/CT. On lesion-based analysis, the sensitivity of 18F-DOPA PET/CT in detecting soft-tissue and bone or bone-marrow metastases was 77% and 86%, respectively-significantly higher than that of 123I-MIBG WBS, at 28% and 69%, respectively. During follow-up, 8 cases of disease progression and 5 deaths occurred. On multivariate analysis, only posttherapeutic 18F-DOPA WBMB (>7.5) was associated with progression-free survival. Conclusion:18F-DOPA PET/CT is more sensitive than 123I-MIBG WBS in staging neuroblastoma patients and evaluating disease persistence after chemotherapy. In a time-to-event analysis, posttherapeutic 18F-DOPA WBMB remained the only risk factor associated with disease progression.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Piccardo A, Morana G, Puntoni M, et al. Diagnosis, Treatment Response, and Prognosis: The Role of 18F-DOPA PET/CT in Children Affected by Neuroblastoma in Comparison with 123I-mIBG Scan: The First Prospective Study. J Nucl Med. 2019. PMID: 31541036. doi:10.2967/jnumed.119.232553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。